- Design
- Systematic review and meta-analysis of prevalence (cross-sectional and cohort studies)
- Population
- 52 studies, 91,913 men with prostate cancer at all stages
- Primary outcome
- Pooled prevalence of osteoporosis and low bone mass
- Effect
- Osteoporosis 22.0% (95% CI 19.9-24.1); low bone mass 41.7% (36.6-46.9); I-squared >95%
A meta-analysis of 52 studies and 91,913 men with prostate cancer pooled the prevalence of reduced bone density, much of it relevant to androgen-deprivation therapy, which accelerates bone loss.
Osteoporosis was present in about 22% (95% CI 19.9-24.1) and low bone mass in about 42% (36.6-46.9), though heterogeneity was very high and driven largely by differing measurement methods and definitions. The analysis reported prevalence only, not fracture rates or the effect of any intervention.
The practical reminder is to build bone health into prostate cancer care: assess bone density before and during androgen-deprivation therapy, ensure calcium and vitamin D adequacy, counsel on lifestyle, and consider bone-protective therapy in those at high fracture risk per local guidance. The data establish that the problem is common, not which treatment prevents fractures.
- About 22% of men with prostate cancer had osteoporosis and 42% low bone mass.
- Androgen-deprivation therapy accelerates the bone loss behind these figures.
- Assess bone density before and during androgen-deprivation therapy.
- Ensure calcium and vitamin D adequacy and address lifestyle risks.
- Consider bone-protective therapy in those at high fracture risk per local guidance.
Why it matters
It quantifies a frequently under-managed harm of hormonal prostate cancer therapy.
Don't overread it
Prevalence only, with large heterogeneity; it does not show that any specific intervention reduces fractures.
The statistics, in plain English
These are pooled prevalence figures with very high heterogeneity, so read them as showing the problem is common rather than as precise rates; the study did not measure fractures or whether treatment prevents them.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free